high mobility group nucleosomal binding domain 2 pseudogene 38Genealiases: []
Q-omics provides the consensus-scored HMGN2P38 profile across patient tissues and cancer cell-line models. HMGN2P38 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, HMGN2P38 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, HMGN2P38 RNA expression shows 10,212 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight SKCM, HNSC, and PDAC as cancer lineages where HMGN2P38 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HMGN2P38 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HMGN2P38 survival associations across molecular data types. HMGN2P38 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HMGN2P38 RNA expression–survival associations across cancer types. High HMGN2P38 expression shows unfavorable associations in UVM, LIHC, LUSC and LGG, but favorable associations in SKCM and UCS. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for HMGN2P38 RNA expression.
This table summarizes HMGN2P38 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for HMGN2P38. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HMGN2P38 shows lower tumor expression in COAD and higher tumor expression in HNSC, STAD, READ, BRCA and LUAD. The HNSC box plot shows higher HMGN2P38 RNA expression in tumor versus normal tissue (log2 FC = +0.128, t-test p = .014).
This table shows molecular features associated with HMGN2P38 in patient tissues and cancer cell lines. In patient samples, HMGN2P38 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set.
